Experimental cancer drug trial halted early
Disease control
Terminated
This early-stage trial tested a new drug called ACTM-838 in 10 people with advanced solid tumors that had stopped responding to standard treatments. The study aimed to find a safe dose and check for side effects. The trial was terminated early, so results are limited.
Phase: PHASE1 • Sponsor: Actym Therapeutics, Inc. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC